ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1297

Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data

Amanda M. Eudy1, Michelle Petri2, Rebecca Fischer-Betz3, Abeer Mokbel4, Cecilia Nalli5, Laura Andreoli5, Angela Tincani6, Yair Molad7, Stephen Balevic8 and Megan E. B. Clowse1, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, 4Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, 5Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 6Spedali Civili and University of Brescia, Brescia, Italy, 7Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 8Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Hydroxychloroquine, meta-analysis, pregnancy and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis remains unknown. The goal of this individual participant meta-analysis was to pool data from multiple prospective cohorts to answer the clinical question of whether hydroxychloroquine (HCQ) treatment is beneficial from the decision point of the first trimester.

Methods: PubMed, Embase, and the Cochrane Database of Systematic Reviews were searched for prospective cohorts of pregnancies among women with lupus. Data from each cohort were collected and analyzed individually. HCQ use was defined as use any time during pregnancy. Outcomes of interest included fetal loss, preterm birth (<37 weeks gestation), and high disease activity (PGA ever >1, SLEDAI ever >4, or a report of a flare, depending on available data). Logistic regression models estimated log odds ratios (OR) and standard errors individually in all cohorts. Pooled ORs were calculated by random-effect models using the generic inverse variance method in Review Manager. Primary analysis included only women with first trimester visits (5 cohorts). Sensitivity analyses included all women (6 cohorts), and subgroup analyses included patients with a history of nephritis.

Results: 46 potential cohorts were identified from 2811 manuscripts. Seven cohorts met inclusion criteria and agreed to participate. The current analysis included 811 pregnancies from six cohorts, of which 70% were exposed to HCQ during pregnancy.

Fetal Loss: When limited to only patients with a 1st trimester visit, a 52% decrease in fetal loss was observed (OR: 0.48; 95% CI: 0.24, 0.94; Table 1).  Among all patients there was a modest decrease in fetal loss among HCQ users, but the association was stronger among women with a history of nephritis (Figure 1).

Preterm Birth: No association with HCQ use during pregnancy and preterm birth was observed among women with a 1st trimester visit (OR: 0.78; 95% CI: 0.47, 1.30), among all women, and among women with nephritis.

Disease Activity: Among patients with a 1st trimester visit, there was a decrease in high disease activity among HCQ users (OR: 0.62; 95% CI: 0.37, 1.05), particularly among women with a history of nephritis. Among all patients, there was no association of HCQ use and high disease activity during pregnancy.

Conclusion: Our results suggest that HCQ may decrease the risk of fetal loss, and the benefits are seen most among women with nephritis. The heterogeneity of data collection suggests a unified approach to identify larger cohorts of lupus pregnancies is needed.

 


Disclosure: A. M. Eudy, None; M. Petri, None; R. Fischer-Betz, None; A. Mokbel, None; C. Nalli, None; L. Andreoli, None; A. Tincani, None; Y. Molad, None; S. Balevic, None; M. E. B. Clowse, None.

To cite this abstract in AMA style:

Eudy AM, Petri M, Fischer-Betz R, Mokbel A, Nalli C, Andreoli L, Tincani A, Molad Y, Balevic S, Clowse MEB. Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/hydroxychloroquine-in-lupus-pregnancy-a-meta-analysis-of-individual-participant-data/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hydroxychloroquine-in-lupus-pregnancy-a-meta-analysis-of-individual-participant-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences